Table 1. Characteristics and outcomes of patients who received diuretic therapy and those who did not before matching.
| Variable | No diuretics N = 5818 | Diuretic N = 929 | Total = N 6747 | P-value |
|---|---|---|---|---|
| Age; Median (IQR) | 65 (54, 74) | 68 (57, 78) | 65 (55, 75) | < .0011 |
| Gender, F, n (%) | 2526 (43%) | 400 (43%) | 2926 (43%) | .82 |
| CKD-EPI eGFR; Median (IQR) | 78 (57, 96) | 74 (53, 94) | 78 (57, 96) | < .0011 |
| Oliguria, n (%) | 1430 (25%) | 465 (50%) | 1895 (29%) | < .0012 |
| Advanced oxygen therapy, n (%) | 1906 (33%) | 718 (77%) | 2624 (39%) | < .0012 |
| Min Lactate on inclusion | 1.5 (1.3, 1.7) | 1.5 (1.2, 1.8) | 1.5 (1.3, 1.7) | .91 |
| Minimum P/F ratio; Median (IQR) | 191 (165, 223) | 173 (144, 200) | 191 (162, 219) | < .0011 |
| SOFA Score; Median (IQR) | 7 (4, 10) | 9 (7, 11) | 8 (5, 11) | < .0011 |
| APACHE III Score; Median (IQR) | 49 (36, 64) | 53 (39, 68) | 49 (36, 65) | < .0011 |
| Total Norepinephrine equivalent dose mcg/kg; Median (IQR) | 53 (20, 131) | 39 (11, 90) | 51 (19, 125) | < .0011 |
| Day 1 Fluid Balance ml, (IQR) | 2790 (1138, 5410) | -116 (-1551, 1164) | 2361 (654, 4944) | < .0011 |
| Day 1 Urine output ml, (IQR) | 1532 (848, 2667) | 2532 (1172, 3892) | 1616 (864, 2863) | < .001 |
| Day 2 Fluid Balance ml, (IQR) | 329 (-451, 1432) | -208 (-1481, 682) | 247 (-603, 1335) | < .0011 |
| Day 2 Urine output ml, (IQR) | 1250 (630, 2277) | 2054 (913, 3448) | 1616 (864, 2863) | < .001 |
| Day 3 Fluid Balance ml, (IQR) | -43 (-981, 788) | -249 (-1456, 579) | -72 (-1062, 761) | < .0011 |
| Day 3 Urine output ml, (IQR) | 1517 (663, 2772) | 2089 (962, 3346) | 1616 (864, 2863) | < .001 |
| Total UOP 6 hours before time zero, ml, (IQR) | 222 (44, 499) | 252 (133, 481) | 226 (57, 497) | 0.6 |
| Total UOP 6 hours after time zero, ml, (IQR) | 390 (185, 811) | 710 (309, 1290) | 422 (196, 874) | <0.001 |
| Average hourly UOP 6 hours before time zero, ml, (IQR) | 37 (7, 83) | 42 (22, 80) | 38 (10, 83) | 0.6 |
| Average hourly UOP 6 hours after time zero, ml, (IQR) | 65 (31, 135) | 118 (52, 215) | 70 (33, 146) | <0.001 |
| Urine output Hour 2, ml, (IQR) | 40 (0, 122) | 112 (23, 319) | 46 (2, 147) | < .001 |
| Urine output Hour 3, ml, (IQR) | 47 (4, 132) | 101 (20, 244) | 52 (6, 147) | < .001 |
| Urine output Hour 4, ml, (IQR) | 48 (6, 124) | 81 (16, 203) | 51 (7, 132) | < .001 |
| Urine output Hour 5, ml, (IQR) | 46 (6, 121) | 82 (16, 195) | 49 (7, 133) | < .001 |
| Urine output Hour 6, ml, (IQR) | 46 (4, 111) | 75 (17, 172) | 49 (6, 121) | < .001 |
| Volume overload at time zero (>5% weight gain since admission), n (%) | 454 (8%) | 354 (38%) | 808 (12%) | < .001 |
| Volume overload at time zero (>10% weight gain since admission), n (%) | 203 (4%) | 201 (22%) | 404 (6%) | < .001 |
| AKI Stage III Day 0 to 7 n (%) | 941 (16%) | 268 (29%) | 1209 (18%) | < .0012 |
| RRT Day 0 to 7 n (%) | 415 (7%) | 118 (13%) | 533 (8%) | < .0012 |
1Wilcoxon rank sum p-value
2Chi-Square p-value